Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where J.P. Williams is active.

Publication


Featured researches published by J.P. Williams.


International Journal of Radiation Oncology Biology Physics | 2001

Circulating IL-6 as a predictor of radiation pneumonitis.

Yuhchyau Chen; Philip Rubin; J.P. Williams; Eric Hernady; Therese Smudzin; Paul Okunieff

PURPOSE We report results from a clinical research protocol investigating circulating pro-inflammatory cytokines (interleukin-6 [IL-6] and tumor necrosis factor alpha [TNFalpha]) in relation to radiation pulmonary injury. METHODS AND MATERIALS In a protocol for cytokine measurement, 25 patients had clinical follow-up longer than 12 months, and 24 had serial cytokine data. Serial plasma specimens before, during, and after thoracic radiotherapy were analyzed for IL-6 and TNFalpha using enzyme-linked immunosorbent assay (ELISA). Radiation pulmonary injury was defined using National Cancer Institute Common Toxicity Criteria. RESULTS Of the 24 patients, 6 had Grade 1 pneumonitis, and 13 had Grade 2 pneumonitis. There was no Grade 3/4 pneumonitis. Median time of radiation pneumonitis was between 8 and 12 weeks post-therapy. IL-6 levels before, during, and after thoracic radiation therapy were significantly higher in those who developed pneumonitis. In contrast, we did not detect a significant correlation between plasma TNFalpha and radiation pneumonitis. CONCLUSIONS High pretreatment plasma levels of IL-6 predisposed patients to the risk of radiation pneumonitis. Pretreatment IL-6 level may serve as a predictor for radiation pneumonitis. Serial plasma IL-6 was consistently higher for the pneumonitis group. The role of IL-6 in the cytokine cascades that promote radiation pulmonary injury deserves further investigation.


Journal of Clinical Oncology | 1995

Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years.

Bruce E. Johnson; R I Linnoila; J.P. Williams; David Venzon; Paul Okunieff; G B Anderson; G E Richardson

PURPOSE Patients who survived small-cell lung cancer (SCLC) for more than 2 years were evaluated to determine the frequency and anatomic pattern of redevelopment of small-cell cancer and development of non-small-cell lung cancer (NSCLC) and aerodigestive cancers with the passage of time. PATIENTS AND METHODS From April 1973 through December 1991, 578 patients with previously untreated SCLC were entered onto prospective therapeutic trials at the National Cancer Institute (NCI), Bethesda, MD. Sixty-two (11%) were cancer-free 2 years after initiation of therapy and were assessable for redevelopment of SCLC and development of NSCLC, and aerodigestive cancers. RESULTS Twenty patients redeveloped SCLC 2.0 to 12.2 years after initiation of chemotherapy, of whom two patients were deemed to have a second primary small-cell cancer that involved the aerodigestive tract. Fifteen patients developed 16 cancers in the lung other than SCLC 3.4 to 14.9 years after initiation of therapy. Two developed other aerodigestive cancers that involved the larynx and lip. The risk of a NSCLC and aerodigestive cancer in these patients increased more than sixfold from 2% per patient per year during years 2 to 4 to 12.6% and 14.4%, respectively, after more than 10 years. The cumulative actuarial risk of a second primary NSCLC or aerodigestive cancer at 16 years is 69% and 72%, respectively. CONCLUSION The increasing risk of second aerodigestive cancers with the passage of time is a mounting problem for patients cured of SCLC. Chemoprevention trials for these patients should be considered.


International Journal of Radiation Oncology Biology Physics | 1994

Biochemical markers as predictors for pulmonary effects of radiation

S. McDonald; P. Rubin; Louis S. Constine; J.P. Williams; Therese Smudzin


International Journal of Radiation Oncology Biology Physics | 2001

Results of a large animal study examining the effects of external beam irradiation on the inhibition of intimal hyperplasia in a prosthetic arterial bypass model at 1 and 3 months

J.P. Williams; Karl A. Illig; Eric Hernady; J.M. LeBlanc; Arvind Soni; Michael C. Schell; P. Rubin; Richard M. Green; Paul Okunieff


International Journal of Radiation Oncology Biology Physics | 1999

14 Circulating humoral factors and lymphocyte subsets as markers for radiation pulmonary injury

Yuhchyau Chen; Ivan Ding; J.P. Williams; J.Z. Sun; Eric Hernady; Therese Smudzin; Peter C. Keng; P. Rubin; Paul Okunieff


International Journal of Radiation Oncology Biology Physics | 2013

Differential Rates of Tissue Development in Children: Predicting Periods of Heightened Tissue Vulnerability to Radiation Injury

D. Sughosh; J.P. Williams; P. Rubin; Louis S. Constine


International Journal of Radiation Oncology Biology Physics | 2012

The Role of Bone Marrow-derived Progenitor Cells in the Systemic Response to Radiation-induced Lung Damage

S.A. Krueger; Jacob N. Finkelstein; J.P. Williams; George D. Wilson; Brian Marples


International Journal of Radiation Oncology Biology Physics | 2010

Pulmonary Immunohistochemistry and Multi-plex Analysis of Circulating Cytokines after Low-Dose Whole-Body Exposures in C57/BL6 Mice

Brian Marples; L. Downing; K.E. Sawarynski; M.D. Sims; George D. Wilson; Jacob N. Finkelstein; J.P. Williams


International Journal of Radiation Oncology Biology Physics | 2009

A New Rapid Methodology for Assessing Pulmonary Damage following Low-dose X-irradiation

Brian Marples; L. Downing; George D. Wilson; A. Martinez; J.P. Williams; Jacob N. Finkelstein


International Journal of Radiation Oncology Biology Physics | 2003

Role of the recruited bone marrow-derived alveolar macrophage and the chemokine receptor, CCR2, in the development of pulmonary late radiation effects in a mouse model

J.P. Williams; Eric Hernady; M Levitt; Carl J. Johnston; Christina K. Reed; Paul Okunieff; Jacob N. Finkelstein

Collaboration


Dive into the J.P. Williams's collaboration.

Top Co-Authors

Avatar

P. Rubin

University of Rochester

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eric Hernady

University of Rochester Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jacob N. Finkelstein

University of Rochester Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge